Accounts Payable and Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2024

Accounts Payable and Accrued Expenses

Schedule of Accounts Payable and Accrued Expenses

	December 31,
($ in thousands)	2024		2023
Accounts payable	$	7,464	$	6,322
Accrued research and development		330		4,118
Accrued compensation		93		2,838
Other (1)		1,599		739
Total accounts payable and accrued expenses	$	9,486	$	14,017

⁽¹⁾ Other includes approximately $1.3 million of accrued consideration for the uBriGene Asset Purchase Agreement, see Note 5.